The Manufacturers Life Insurance Company Makes New $3.82 Million Investment in Enliven Therapeutics, Inc. $ELVN

The Manufacturers Life Insurance Company bought a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 75,265 shares of the company’s stock, valued at approximately $3,820,000.

Several other hedge funds and other institutional investors also recently modified their holdings of ELVN. KBC Group NV bought a new position in shares of Enliven Therapeutics during the first quarter worth about $38,000. BNP Paribas Financial Markets lifted its position in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in Enliven Therapeutics during the 4th quarter valued at about $83,000. Quantbot Technologies LP boosted its stake in Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Enliven Therapeutics in the 4th quarter worth about $95,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $58.58, for a total value of $352,534.44. Following the sale, the chief financial officer owned 40,036 shares of the company’s stock, valued at approximately $2,345,308.88. The trade was a 13.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mika K. Derynck sold 158,795 shares of the company’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $60.21, for a total value of $9,561,046.95. Following the completion of the sale, the director owned 87,373 shares of the company’s stock, valued at approximately $5,260,728.33. This trade represents a 64.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 196,849 shares of company stock worth $11,344,257 over the last ninety days. Company insiders own 3.00% of the company’s stock.

Enliven Therapeutics Trading Down 0.1%

Enliven Therapeutics stock opened at $57.86 on Wednesday. The stock has a market cap of $4.24 billion, a price-to-earnings ratio of -34.65 and a beta of 0.30. The company’s 50-day moving average price is $55.04 and its two-hundred day moving average price is $43.62. Enliven Therapeutics, Inc. has a 52 week low of $14.78 and a 52 week high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Research analysts expect that Enliven Therapeutics, Inc. will post -1.69 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on ELVN. Guggenheim dropped their price target on shares of Enliven Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Stifel Nicolaus increased their price objective on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. JonesTrading lifted their target price on Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, June 29th. Finally, Barclays initiated coverage on Enliven Therapeutics in a research report on Tuesday, August 18th. They set an “overweight” rating and a $78.00 price target for the company. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $75.00.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.